Fundamentals of Liver Disease- Non-Alcoholic Fatty Liver Disease & Non-Alcoholic Steatohepatitis
- Registration Closed
There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.
The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.
Key topic areas:
NAFLD: Diagnosis and Identification of Those at Risk of Disease Progression
Pathogenesis of Non-alcoholic Steatohepatitis
Non-Invasive Determination of Advanced Disease in NAFLD
Lifestyle Interventions: Setting Goals and Recommendations
Comorbidities in NAFLD: Cardiovascular Disease, Sleep Apnea, and Chronic Kidney Disease
Bariatric Surgery: Is the Cure for NASH in the OR?
Managing NASH Cirrhosis and Assessment for Liver Transplant
Current Pharmacological Treatment Options for Non-Alcoholic Steatohepatitis (NASH)
Emerging Treatments for Non-Alcoholic Steatohepatitis
Online presentations comprised of PowerPoint slides and accompanying audio and online pre- and post-tests and evaluations:
-9 online interactive, narrated modules 15 to 20 minutes in length
-Pre- and post-test questions for each module
Method of Participation
Each learner will listen to each audio self-directed module while following along with the visual slides. Upon completion, each learner will answer evaluation questions and pass a post-test with at least a score of 70% to receive their certificate.
Original release date: May 4, 2017
Expiration date: May 3, 2019
Time to complete each module: 15-20 minutes
All faculty in this activity have given their permission for publication OR
For questions on CE credit for this activity, email Certificate@AmedcoEmail.com
For questions on MOC/CME/CE content or the activity web site, contact firstname.lastname@example.org
The Non-Alcoholic Fatty Liver Disease & Non-Alcoholic Steatohepatitis unit of the Fundamentals of Liver Disease currently does not offer CME, CE or MOC. This unit is available for viewing purposes only. A newly updated version will be available soon for credits or points. Check back for updates!
Mary E. McCarthy Rinella
Arun J. Sanyal
Leon A. Adams
Brent A. Tetri
Kathleen E. Corey
Dawn M. Torres
Stephen A. Harrison
• Identify patients with liver disease, specifically NASH/NAFLD
• Apply diagnostic tests appropriately
• Discuss important counseling
• Recognize treatment/referral priorities
• Identify first line therapies for NASH/NAFLD
• Refer to specialist in a timely and appropriate fashion
This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.
Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AASLD designates this enduring activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
American Board of Internal Medicine (ABIM) MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pediatrics (ABP) MOC Statement
“Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 4.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.”
MOC Points Process
Physicians seeking MOC points must complete the CME evaluation in addition to completing the pre-test(s), viewing all of the presentation(s) and successfully passing the post-test(s) for each module with a score of 70% or better. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month. Your MOC points will NOT be reported to ABIM and/or ABP until you are completely done with all lectures and the “Final Evaluation & Certificate/Completion Confirmation” step.
Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This course is co-provided by Amedco and the American Association for the Study of Liver Diseases. Maximum of number of 4.5 hours.
You must complete the pre-test(s), view all of the presentation(s), successfully pass all of the post-test(s) for each module with a score of 70% or better and complete an evaluation to receive a certificate of completion.
DISCLOSURE OF CONFLICTS OF INTEREST
AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
The organizers and faculty have reported the following disclosures:
Dr. Mary Rinella
Consulting: AbbVie, Fibrogen, NGM Biopharmaceuticals, Novartis, Gilead, Intercept, and Takeda
Editorial Board: Hepatology, Clinical Liver Disease (guest associate editor), Seminars in Liver Disease (associate editor in 2017)
Dr. Arun Sanyal
Consulting: Novartis, Merck, BMS, Boehringer Ingelheim, Nitto Denko, Tobira, Intercept, Genfit, Aredelyx, Akarna, Syntlogic, Fractyl, Pfizer, Jannsen, Exalenz, Novo Nordisk, Nordic Bioscience, Lilly
Grant/research support: Intercept, Gilead, Tobira, Novartis, Astra Zeneca, Merck, BMS
Stock Options: Genfit
President of Sanyal Bio
Dr. Leon Adams
Patents regarding Hepascore
Employer has a licensing agreement with Quest Diagnostics regarding its commercialization
Dr. Brent Neuschwander-Tetri
Consulting: Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Conatus, Consynance, Galmed, Janssen, Karos, Medimmune, Nimbus, Novartis, Pfizer, Receptos, Tobira, and Zafgen
Dr. Kathleen Corey
Nothing to disclose
Dr. Philippe Mathurin
Financial Interests: MSD, Abbvie, Gilead Sciences, Bristol-Myers Squibb, Verlyx, Intercept, Janssen-Cilag, and Bayer Healthcare pharmaceutical companies
Dr. Kymberly Watt
Co-investigator for industry studies supported by Conatus, Intercept Pharmaceuticals, and Gilead
Dr. Dawn Torres
Nothing to disclose
Dr. Stephen Harrison
Financial Relationships: Advisory/Consulting: Gilead, Fibrogen, NGM Biopharm, Nimbus Discovery, Pfizer, Zafgen, Medivation, Intercept, CLDF, Merck, Genfit, Perspectum, Echosens, Madrigal
Speaker’s Bureau: Abbvie, Alexion
Nothing to disclose
Nothing to disclose
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Acknowledgement of Commercial Support:
No commercial support was received for this enduring material activity.